425: TenX Keane Acquisition Secures Additional Extension for Business Combination with Citius Pharma

TenX Keane Acquisition receives a third one-month extension for its business combination with Citius Pharmaceuticals via a $66,667 deposit.

Summary

• TenX Keane Acquisition secured a third one-month extension to complete its business combination.
• Citius Pharma deposited $66,667 into TenX Keane Acquisition's trust account on June 17, 2024, extending the deadline to July 18, 2024.
• This extension is the third of a possible seven, each requiring a deposit of $66,667.
• The deposit is evidenced by an unsecured promissory note from TenX Keane Acquisition to Citius Pharma.
• The promissory note bears no interest and is repayable according to the terms of the Merger Agreement.
• The original deadline to consummate the business combination was April 18, 2024, but could be extended up to seven months to November 18, 2024 with monthly deposits.
• The Merger Agreement between TenX Keane Acquisition and Citius Pharmaceuticals was initially dated October 23, 2023.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the extension provides more time, the need for multiple extensions introduces uncertainty. The financial commitment from Citius Pharma is a positive sign, but the contingent repayment of the promissory note adds a layer of risk.

Positives

• The extension provides additional time for TenX Keane Acquisition and Citius Pharmaceuticals to finalize their business combination.
• Citius Pharma's continued financial support demonstrates commitment to the merger.

Negatives

• The need for multiple extensions may indicate challenges in completing the business combination within the original timeframe.
• The repeated deposits of $66,667 are a recurring expense for Citius Pharma.

Risks

• Failure to complete the business combination by the extended deadline could lead to the termination of the Merger Agreement.
• The promissory note's repayment is contingent on the Trust Account balance exceeding $2,000,000 at the closing of the merger, creating uncertainty.
• Events of default outlined in the promissory note could trigger immediate repayment obligations.

Future Outlook

The future outlook depends on the successful completion of the business combination by July 18, 2024, or any further extensions secured.

Industry Context

This announcement is typical for SPACs nearing their business combination deadline, often requiring extensions to finalize deals. The repeated extensions suggest potential complexities in the merger process.

Comparison to Industry Standards

• SPACs often use extension options to provide more time for deal completion, but multiple extensions can raise concerns about the deal's viability.
• The $66,667 monthly extension fee is relatively standard for SPACs of this size, aligning with industry practices for incentivizing deal completion.
• Comparable SPACs, such as those merging with biotech companies, often face similar challenges in meeting deadlines due to regulatory hurdles and market conditions.

Related Party Transactions

• The deposit from Citius Pharma, the company being acquired, to extend the deadline is a related party transaction.

Stakeholder Impact

• Shareholders of TenX Keane Acquisition are impacted by the extension, as it affects the timeline for the potential merger and the value of their investment.
• Citius Pharmaceuticals is impacted as they are providing the funds for the extension and are party to the merger agreement.

Next Steps

• TenX Keane Acquisition and Citius Pharmaceuticals need to finalize the business combination before the extended deadline of July 18, 2024.
• Citius Pharma may need to deposit additional funds for further extensions if the deal is not completed by the deadline.

Key Dates